You are here: Home » Companies » News
Business Standard

Dr Reddy's recalls single lot of breast cancer drug Docetaxel from US

The company has recalled the drug on account of defective container, the report said

Dr Reddy Docetaxel

Press Trust of India  |  New Delhi 

reddy, dr reddy's
Dr Reddy's laboratory

Pharmaceuticals major Dr Reddy's Laboratories has recalled a single lot of Docetaxel injection vials, used for treatment of breast cancer, USFDA has said.

As per the US health regulator's enforcement report for the week of January 17, a single lot of 1,051 vials of Docetaxel injection USP, 20 mg/mL was distributed in the US, Uzbekistan and Myanmar.

The company has recalled the drug on account of defective container, the report said.

"Product complaints received of defect in the seal of the Docetaxel injection vials that the aluminium seal and/or stopper is removed when the cap is flipped off," it said.

The vials were manufactured by Dr Reddy's Laboratories at its Visakhapatnam facility, the United States Food and Drug Administration has said.

The voluntary ongoing recall is a class II recall, the regulator said.

As per the USFDA, a class II recall is initiated in a situation, "in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote".

Shares of the company were trading 1.23 per cent higher at Rs 2,492.05.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Wed, January 17 2018. 16:19 IST